Download MendeleyA novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1.
Numata, M., Haginoya, N., Shiroishi, M., Hirata, T., Sato-Otsubo, A., Yoshikawa, K., Takata, Y., Nagase, R., Kashimoto, Y., Suzuki, M., Schulte, N., Polier, G., Kurimoto, A., Tomoe, Y., Toyota, A., Yoneyama, T., Imai, E., Watanabe, K., Hamada, T., Kanada, R., Watanabe, J., Kagoshima, Y., Tokumaru, E., Murata, K., Baba, T., Shinozaki, T., Ohtsuka, M., Goto, K., Karibe, T., Deguchi, T., Gocho, Y., Yoshida, M., Tomizawa, D., Kato, M., Tsutsumi, S., Kitagawa, M., Abe, Y.(2023) Cancer Cell Int 23: 36-36
- PubMed: 36841758
- DOI: https://doi.org/10.1186/s12935-023-02877-y
- Primary Citation of Related Structures:
8IG0 - PubMed Abstract:
Mixed lineage leukemia 1-rearranged (MLL1-r) acute leukemia patients respond poorly to currently available treatments and there is a need to develop more effective therapies directly disrupting the Menin‒MLL1 complex. Small-molecule-mediated inhibition of the protein‒protein interaction between Menin and MLL1 fusion proteins is a potential therapeutic strategy for patients with MLL1-r or mutated-nucleophosmin 1 (NPM1c) acute leukemia. In this study, we preclinically evaluated the new compound DS-1594a and its salts. We evaluated the preclinical efficacy of DS-1594a as well as DS-1594a·HCl (the HCl salt of DS-1594a) and DS-1594a·succinate (the succinic acid salt of DS-1594a, DS-1594b) in vitro and in vivo using acute myeloid leukemia (AML)/acute lymphoblastic leukemia (ALL) models. Our results showed that MLL1-r or NPM1c human leukemic cell lines were selectively and highly sensitive to DS-1594a·HCl, with 50% growth inhibition values < 30 nM. Compared with cytrabine, the standard chemotherapy drug as AML therapy, both DS-1594a·HCl and DS-1594a·succinate mediated the eradication of potential leukemia-initiating cells by enhancing differentiation and reducing serial colony-forming potential in MLL1-r AML cells in vitro. The results were confirmed by flow cytometry, RNA sequencing, RT‒qPCR and chromatin immunoprecipitation sequencing analyses. DS-1594a·HCl and DS-1594a·succinate exhibited significant antitumor efficacy and survival benefit in MOLM-13 cell and patient-derived xenograft models of MLL1-r or NPM1c acute leukemia in vivo. We have generated a novel, potent, orally available small-molecule inhibitor of the Menin-MLL1 interaction, DS-1594a. Our results suggest that DS-1594a has medicinal properties distinct from those of cytarabine and that DS-1594a has the potential to be a new anticancer therapy and support oral dosing regimen for clinical studies (NCT04752163).
Organizational Affiliation:
Shinagawa R&D Center, Daiichi Sankyo Co., Ltd, 1-2-5 Hiromachi, Shinagawa-Ku, Tokyo, 140-0005, Japan.
